MX373982B - Composiciones y metodos para formas de liofilos de nanoparticulas. - Google Patents

Composiciones y metodos para formas de liofilos de nanoparticulas.

Info

Publication number
MX373982B
MX373982B MX2018000891A MX2018000891A MX373982B MX 373982 B MX373982 B MX 373982B MX 2018000891 A MX2018000891 A MX 2018000891A MX 2018000891 A MX2018000891 A MX 2018000891A MX 373982 B MX373982 B MX 373982B
Authority
MX
Mexico
Prior art keywords
nucleic acid
active agents
acid active
compositions
lyophil
Prior art date
Application number
MX2018000891A
Other languages
English (en)
Spanish (es)
Other versions
MX2018000891A (es
Inventor
Dong Liu
Haiqing Yin
Liping Wang
Roger Adami
Wenbin Ying
Yuwei Wang
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of MX2018000891A publication Critical patent/MX2018000891A/es
Publication of MX373982B publication Critical patent/MX373982B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018000891A 2015-07-22 2016-07-22 Composiciones y metodos para formas de liofilos de nanoparticulas. MX373982B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
PCT/US2016/043537 WO2017015552A1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms

Publications (2)

Publication Number Publication Date
MX2018000891A MX2018000891A (es) 2018-06-11
MX373982B true MX373982B (es) 2020-07-15

Family

ID=57834582

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000891A MX373982B (es) 2015-07-22 2016-07-22 Composiciones y metodos para formas de liofilos de nanoparticulas.

Country Status (23)

Country Link
US (3) US10300018B2 (https=)
EP (1) EP3324932B1 (https=)
JP (2) JP6875373B2 (https=)
KR (1) KR102716928B1 (https=)
CN (2) CN108024957B (https=)
AU (1) AU2016297153B2 (https=)
CA (1) CA2992849C (https=)
CY (1) CY1123984T1 (https=)
DK (1) DK3324932T3 (https=)
EA (1) EA035761B1 (https=)
ES (1) ES2862191T3 (https=)
HR (1) HRP20210523T1 (https=)
HU (1) HUE053990T2 (https=)
IL (2) IL288342B2 (https=)
LT (1) LT3324932T (https=)
MX (1) MX373982B (https=)
PL (1) PL3324932T3 (https=)
PT (1) PT3324932T (https=)
RS (1) RS61607B1 (https=)
SI (1) SI3324932T1 (https=)
SM (1) SMT202100196T1 (https=)
TW (1) TWI732773B (https=)
WO (1) WO2017015552A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100196T1 (it) * 2015-07-22 2021-05-07 Nitto Denko Corp Composizioni e metodi per forme liofile di nanoparticelle
IL275334B2 (en) 2017-12-12 2026-04-01 Lead Biotherapeutics Ltd Solid lipid nanoparticles for intracellular release of active ingredients and method for their production
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
CN112789031B (zh) 2018-09-28 2023-03-24 胡桃钳医疗公司 用于核酸递送的包含脂化的阳离子肽化合物的脂质纳米颗粒制剂
EP4365289A3 (en) * 2018-11-16 2024-07-10 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
WO2021060440A1 (ja) * 2019-09-26 2021-04-01 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
WO2021174149A2 (en) * 2020-02-28 2021-09-02 Microcures, Inc. Fidgetin-like 2 as a target to enhance wound healing
EP4138791A1 (en) * 2020-04-20 2023-03-01 Board of Regents, The University of Texas System Biologically active dry powder compositions and method of their manufacture and use
US12178921B2 (en) * 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
JPWO2022071582A1 (https=) 2020-10-02 2022-04-07
WO2023064891A1 (en) 2021-10-14 2023-04-20 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
KR102712873B1 (ko) * 2021-12-20 2024-10-04 고려자연식품(주) 과일향기 포집을 위한 나노 지질 전달체 제조와 분말화 방법
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
US20240254485A1 (en) 2023-01-13 2024-08-01 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
AU2024296743A1 (en) * 2023-07-13 2026-02-26 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
BRPI0314042B8 (pt) * 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
PT1633327E (pt) * 2003-06-04 2010-11-08 Univ Georgetown Método para melhoramento da estabilidade e duração de armazenamento de complexos lipossomais
AU2005302255A1 (en) 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
EP1811960A2 (en) 2004-11-19 2007-08-01 Novosom AG Improvements in or relating to pharmaceutical compositions for local administration
WO2008096779A1 (ja) * 2007-02-09 2008-08-14 National University Corporation NARA Institute of Science and Technology Ｃ７０含有リポソームおよびその製造方法、並びにその利用
US8357401B2 (en) * 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
EP3354644A1 (en) * 2011-06-08 2018-08-01 Translate Bio, Inc. Cleavable lipids
EP3572071A1 (en) 2011-10-21 2019-11-27 Jazz Pharmaceuticals Research LLC Lyophilized liposomes
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
CA2853685C (en) 2011-11-04 2019-09-03 Nitto Denko Corporation Single use system for sterilely producing lipid-nucleic acid particles
NZ630219A (en) 2012-03-28 2016-09-30 Discovery Lab Inc Lyophilization of synthetic liposomal pulmonary surfactant
HK1206644A1 (en) * 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
SI2858974T1 (sl) 2012-06-08 2019-01-31 Nitto Denko Corporation Lipidi za formulacije za dostavo terapevtskega sredstva
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
SMT202100196T1 (it) * 2015-07-22 2021-05-07 Nitto Denko Corp Composizioni e metodi per forme liofile di nanoparticelle

Also Published As

Publication number Publication date
US20240000710A1 (en) 2024-01-04
JP6875373B2 (ja) 2021-05-26
JP7268079B2 (ja) 2023-05-02
CA2992849A1 (en) 2017-01-26
EP3324932A1 (en) 2018-05-30
DK3324932T3 (da) 2021-04-06
CA2992849C (en) 2023-06-13
IL257029B (en) 2021-12-01
MX2018000891A (es) 2018-06-11
TWI732773B (zh) 2021-07-11
JP2018521083A (ja) 2018-08-02
IL257029A (en) 2018-03-29
PT3324932T (pt) 2021-04-06
EA201890367A1 (ru) 2018-06-29
US11737982B2 (en) 2023-08-29
IL288342A (en) 2022-01-01
SI3324932T1 (sl) 2021-07-30
CN113679689A (zh) 2021-11-23
US20190231695A1 (en) 2019-08-01
CN108024957A (zh) 2018-05-11
WO2017015552A1 (en) 2017-01-26
RS61607B1 (sr) 2021-04-29
PL3324932T3 (pl) 2021-07-05
CN113679689B (zh) 2023-09-01
US10300018B2 (en) 2019-05-28
HUE053990T2 (hu) 2021-08-30
ES2862191T3 (es) 2021-10-07
CY1123984T1 (el) 2022-05-27
HRP20210523T1 (hr) 2021-05-14
US20170020819A1 (en) 2017-01-26
TW201717914A (zh) 2017-06-01
EP3324932B1 (en) 2021-03-10
US12311055B2 (en) 2025-05-27
AU2016297153B2 (en) 2021-02-25
SMT202100196T1 (it) 2021-05-07
KR102716928B1 (ko) 2024-10-11
CN108024957B (zh) 2021-08-24
IL288342B1 (en) 2023-10-01
KR20180030698A (ko) 2018-03-23
EP3324932A4 (en) 2019-03-06
EA035761B1 (ru) 2020-08-06
BR112018001178A2 (pt) 2018-09-11
LT3324932T (lt) 2021-04-26
JP2021119161A (ja) 2021-08-12
IL288342B2 (en) 2024-02-01
AU2016297153A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
MX373982B (es) Composiciones y metodos para formas de liofilos de nanoparticulas.
ES2918001R1 (es) Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos
ES3059609T3 (en) Nanoparticle formulations for delivery of nucleic acid complexes
IL262304A (en) Methods for providing single-stranded rna
EP3662913A4 (en) Nucleic-acid-containing lipid nanoparticles
MX2017016088A (es) Oligonucleotidos multi-conjugados definidos.
MX394576B (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn)
MX2016000019A (es) (arnip) gen especifico relacionado con las enfermedades respiratorias, (arnip) que contiene la estructura arn oligo helicoidal, composicion que contiene la misma para prevencion o tratamiento de las enfermedades respiratorias.
MA45188A (fr) Oligonucléotides, compositions et méthodes associées
LT3636764T (lt) 3`utr sekos, skirtos rnr stabilizavimui
MX2017017079A (es) Sistema de administracion dirigida de principio activo celular.
CY1121110T1 (el) Αντινοηματικα-ολιγονουκλεοτιδια ως παρεμποδιστες σηματοδοτησης tgf-r
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
HK1217180A1 (zh) 根據一種核苷轉運載體的水平治療癌症的方法
MX382017B (es) Metodos para el tratamiento de cancer pancreatico.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CL2014000210A1 (es) Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.
WO2015152693A3 (ko) 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
MX2016004285A (es) Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.
MX385871B (es) Composiciones y metodos para inhibir la expresion del gen lect2.
EP3277806A4 (en) Methods of forming nanostructures using self-assembled nucleic acids, and nanostructures thereof
EP3220895A4 (en) The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
DK3294756T3 (da) Retroviral partikel, omfattende mindst to forskellige indkapslede, ikke-virale RNA'er
AR099558A1 (es) Régimen de dosaje del compuesto fgf-18
HK1246303A1 (zh) 反义抗菌化合物和方法

Legal Events

Date Code Title Description
FG Grant or registration